Document is current
Any future updates will be listed below
-
Authors
van Vugt, Marion https://orcid.org/0000-0002-6634-1989
She, Ruicong
Kardys, Isabella
Petersen, Teun B. https://orcid.org/0000-0002-2338-9931
de Bakker, Marie https://orcid.org/0000-0002-4883-2805
Akkerhuis, K. Martijn
Caliskan, Kadir https://orcid.org/0000-0002-3293-9261
Manintveld, Olivier C.
Uijl, Alicia https://orcid.org/0000-0003-2835-7741
van Ramshorst, Jan
Rizopoulos, Dimitris
Umans, Victor AWM
Boersma, Eric
Lanfear, David E.
Asselbergs, Folkert W.
van Setten, Jessica https://orcid.org/0000-0002-4934-7510
Schmidt, A. Floriaan https://orcid.org/0000-0003-1327-0424
-
Funding
Funding for this research was provided by:
Hartstichting (2019T045, 2019T045)
British Heart Foundation (PG/18/5033837, PG/22/10989)
- License Information
-
More Information
Article History
Received: 7 May 2025
Accepted: 21 October 2025
First Online: 20 November 2025
Competing interests
: O.C.M. has served on advisory boards of Abbott, Astra Zeneca, Boehringer Ingelheim, and Novartis. A.F.S. has received funding from New Amsterdam and Servier for unrelated work and is an Editorial Board Member for Communications Medicine but was not involved in the editorial review or peer review, nor in the decision to publish this article. I.K. has received travel reimbursement from SomaLogic and Olink. D.E.L. is a consultant for Astra Zeneca, Bayer, Cytokinetics, Illumina, RyCarma, has participated in research with Akros, AstraZeneca, Cytokinetics, Lilly, Kardigan, Novartis, Pfizer, Somalogic, and has a patent (held by Henry Ford Health) for a beta‐blocker response polygenic score. All other authors declare no competing interest.
